Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Neisseria gonorrhoeae and extended-spectrum cephalosporins in California: surveillance and molecular detection of mosaic penA.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Anti-Bacterial Agents/*pharmacology ; Carrier Proteins/*genetics ; Cephalosporins/*pharmacology ; Gonorrhea/*microbiology ; Neisseria gonorrhoeae/*drug effects ; Neisseria gonorrhoeae/*isolation & purification; Adult ; Alleles ; California/epidemiology ; Ceftriaxone/pharmacology ; Ceftriaxone/therapeutic use ; Drug Resistance, Bacterial ; Genotype ; Gonorrhea/diagnosis ; Gonorrhea/epidemiology ; Humans ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Molecular Epidemiology ; Neisseria gonorrhoeae/genetics ; Serine-Type D-Ala-D-Ala Carboxypeptidase ; Young Adult
    • Abstract:
      Background: The spread of Neisseria gonorrhoeae strains with mosaic penA alleles and reduced susceptibility to extended-spectrum cephalosporins is a major public health problem. While much work has been performed internationally, little is known about the genetics or molecular epidemiology of N. gonorrhoeae isolates with reduced susceptibility to extended-spectrum cephalosporins in the United States. The majority of N. gonorrhoeae infections are diagnosed without a live culture. Molecular tools capable of detecting markers of extended-spectrum cephalosporin resistance are needed.
      Methods: Urethral N. gonorrhoeae isolates were collected from 684 men at public health clinics in California in 2011. Minimum inhibitory concentrations (MICs) to ceftriaxone, cefixime, cefpodoxime and azithromycin were determined by Etest and categorized according to the U.S. Centers for Disease Control 2010 alert value breakpoints. 684 isolates were screened for mosaic penA alleles using real-time PCR (RTPCR) and 59 reactive isolates were subjected to DNA sequencing of their penA alleles and Neisseria gonorrhoeae multi-antigen sequence typing (NG-MAST). To increase the specificity of the screening RTPCR in detecting isolates with alert value extended-spectrum cephalosporin MICs, the primers were modified to selectively amplify the mosaic XXXIV penA allele.
      Results: Three mosaic penA alleles were detected including two previously described alleles (XXXIV, XXXVIII) and one novel allele (LA-A). Of the 29 isolates with an alert value extended-spectrum cephalosporin MIC, all possessed the mosaic XXXIV penA allele and 18 were sequence type 1407, an internationally successful strain associated with multi-drug resistance. The modified RTPCR detected the mosaic XXXIV penA allele in urethral isolates and urine specimens and displayed no amplification of the other penA alleles detected in this study.
      Conclusion: N. gonorrhoeae isolates with mosaic penA alleles and reduced susceptibility to extended-spectrum cephalosporins are currently circulating in California. Isolates with the same NG-MAST ST, penA allele and extended-spectrum cephalosporin MICs have caused treatment failures elsewhere. The RTPCR assay presented here may be useful for the detection of N. gonorrheoae isolates and clinical specimens with reduced extended-spectrum cephalosporin MICs in settings where antimicrobial susceptibility testing is unavailable. In an era of increasing antimicrobial resistance and decreasing culture capacity, molecular assays capable of detecting extended-spectrum cephalosporin of resistance are essential to public health.
    • References:
      JAMA. 2013 Jan 9;309(2):163-70. (PMID: 23299608)
      J Antimicrob Chemother. 2013 Jun;68(6):1267-70. (PMID: 23416957)
      J Microbiol Methods. 2013 Dec;95(3):379-80. (PMID: 24455772)
      Euro Surveill. 2010 Nov 25;15(47):. (PMID: 21144442)
      Sex Transm Infect. 2010 Nov;86(6):454-60. (PMID: 20940159)
      Ann Intern Med. 2013 Mar 5;158(5 Pt 1):321-8. (PMID: 23460055)
      Sex Transm Dis. 2012 Apr;39(4):316-23. (PMID: 22421701)
      Antimicrob Agents Chemother. 2012 Nov;56(11):5633-41. (PMID: 22908152)
      Euro Surveill. 2011 Apr 07;16(14):. (PMID: 21492528)
      Antimicrob Agents Chemother. 2009 Sep;53(9):4032-4. (PMID: 19546370)
      Antimicrob Agents Chemother. 2005 Jan;49(1):137-43. (PMID: 15616287)
      Ann N Y Acad Sci. 2011 Aug;1230:E19-28. (PMID: 22239555)
      Emerg Infect Dis. 2007 Aug;13(8):1275-7. (PMID: 17953118)
      Antimicrob Agents Chemother. 2013 Nov;57(11):5225-32. (PMID: 23939890)
      Euro Surveill. 2013 Jan 17;18(3):. (PMID: 23351652)
      Antimicrob Agents Chemother. 2007 Jun;51(6):2117-22. (PMID: 17420216)
      Euro Surveill. 2011 Feb 10;16(6):. (PMID: 21329645)
      Future Microbiol. 2012 Dec;7(12):1401-22. (PMID: 23231489)
      Expert Opin Pharmacother. 2009 Mar;10(4):555-77. (PMID: 19284360)
      Euro Surveill. 2011 Oct 27;16(43):. (PMID: 22085601)
      J Med Microbiol. 2009 May;58(Pt 5):683-687. (PMID: 19369534)
      Antimicrob Agents Chemother. 2008 Oct;52(10):3564-7. (PMID: 18663018)
      Sex Transm Dis. 2011 Oct;38(10):892-8. (PMID: 21934558)
      N Engl J Med. 2012 Feb 9;366(6):485-7. (PMID: 22316442)
      J Law Med Ethics. 2005 Spring;33(1):125-41. (PMID: 15934670)
      J Antimicrob Chemother. 2012 Aug;67(8):1858-60. (PMID: 22566592)
      Euro Surveill. 2011 Oct 20;16(42):. (PMID: 22027378)
      MMWR Morb Mortal Wkly Rep. 2011 May 13;58(53):1-100. (PMID: 21566560)
      Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45. (PMID: 16940068)
      MMWR Morb Mortal Wkly Rep. 2011 Jul 8;60(26):873-7. (PMID: 21734634)
      MMWR Recomm Rep. 2010 Dec 17;59(RR-12):1-110. (PMID: 21160459)
      Curr Infect Dis Rep. 2011 Apr;13(2):196-204. (PMID: 21365384)
      Expert Rev Anti Infect Ther. 2009 Sep;7(7):821-34. (PMID: 19735224)
      Sex Transm Infect. 2010 Nov;86(6):415-21. (PMID: 20656721)
      Antimicrob Agents Chemother. 2011 Feb;55(2):703-12. (PMID: 21098249)
      Antimicrob Agents Chemother. 2011 Jul;55(7):3538-45. (PMID: 21576437)
      J Clin Microbiol. 2008 May;46(5):1804-10. (PMID: 18367575)
      Euro Surveill. 2012 Jun 21;17(25):. (PMID: 22748003)
      Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80. (PMID: 22155830)
      J Infect Chemother. 2008 Jun;14(3):195-203. (PMID: 18574654)
      Antimicrob Agents Chemother. 2002 Dec;46(12):3744-9. (PMID: 12435671)
      J Infect Dis. 2004 Apr 15;189(8):1497-505. (PMID: 15073688)
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Carrier Proteins)
      0 (Cephalosporins)
      75J73V1629 (Ceftriaxone)
      EC 3.4.16.4 (Serine-Type D-Ala-D-Ala Carboxypeptidase)
      EC 3.4.16.4 (penicillin-binding protein 2, Neisseria gonorrhoeae)
    • Publication Date:
      Date Created: 20131206 Date Completed: 20140925 Latest Revision: 20240321
    • Publication Date:
      20250114
    • Accession Number:
      PMC4235022
    • Accession Number:
      10.1186/1471-2334-13-570
    • Accession Number:
      24305088